Use of ivabradine in a critically ill pediatric patient with recalcitrant ectopic atrial tachycardia and complex congenital heart disease

Hackett, Gretchen L.; Lin, Tracie K.; Imundo, Jason R.

doi:10.1016/j.hrcr.2022.03.011

Cited by 6 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the experience was limited to several case-reports and small series in pediatrics, often with normal cardiac anatomy. (6)(7)(8)(9)(10) Recently, Xu et all reported its single center experience with ivabradine monotherapy in 12 pediatric patients with focal AT and no CHD, who were resistant to conventional antiarrhythmic agents. ( 6) Ivabradine was effective in 50% of the patients, and well tolerated without any events of bradycardia.…”

Section: Clinical Experience With Ivabradinementioning

confidence: 99%

“…However, except for a case-report, outcomes of ivabradine in pediatric with congenital heart disease were unknown. (9) Focal AT are not uncommon in pediatric patients with congenital heart disease, especially in the early post-operative period. (14) In these patients, AT is often associated with hemodynamic comprise and a three times higher mortality rate.…”

Section: Clinical Experience With Ivabradinementioning

confidence: 99%

“…(5) Experience with ivabradine in pediatric patients with focal AT is limited to small case series, often lacking patients with congenital heart disease (CHD). (6)(7)(8)(9)(10)(11) In young patients with CHD, AT is a significant source of morbidity and mortality. (12,13) Multiple anti-arrhythmia agents are moderately effective in treating AT; however, all have potentially significant side effects, which could outweigh their benefits.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease

Tolani,

Ramdat Misier,

Alqahtani

et al. 2024

Heart Rhythm

View full text Add to dashboard Cite

Section: Clinical Experience With Ivabradinementioning

confidence: 99%

Section: Clinical Experience With Ivabradinementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease

Tolani,

Ramdat Misier,

Alqahtani

et al. 2024

Heart Rhythm

View full text Add to dashboard Cite

“…Ivabradine may cause negative inotropic and vasoconstrictive effects, arrhythmias, impaired intracardiac impulse propagation, or arterial hypotension. Rarely, dysphagia has been reported [5][6][7][8][9]. Case reports show beneficial effects in tachyarrhythmias, showing no increase in adverse events compared to use in adults.…”

Section: Review On Antiarrhythmic Drug Dosing In Childrenmentioning

confidence: 99%

“…Dosage of Vaughn-Williams classification 0, Ia, and Ib drugs in children[2,[5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21].…”

mentioning

confidence: 99%

Antiarrhythmic Drug Dosing in Children—Review of the Literature

Oeffl,

Schober,

Faudon

et al. 2023

Children

View full text Add to dashboard Cite

Antiarrhythmic drug therapy represents a mainstay in pediatric arrhythmias. However, official guidelines and consensus documents on this topic remain scarce. There are rather uniform recommendations for some medications (including adenosine, amiodarone, and esmolol), while there are only very broad dosage recommendations for others (such as sotalol or digoxin). To prevent potential mistakes and even uncertainties with regard to dosing, we summarized the published dosage recommendations for antiarrhythmic drugs in children. Because of the wide variations in availability, regulatory approval, and experience, we encourage centers to develop their own specific protocols for pediatric antiarrhythmic drug therapy.

show abstract

Early and Late Postoperative Tachyarrhythmias in Children and Young Adults Undergoing Congenital Heart Disease Surgery

et al. 2022

View full text Add to dashboard Cite

The population of patients with congenital heart disease is constantly growing with an increasing number of individuals reaching adulthood. A significant proportion of these children and young adults will suffer from tachyarrhythmias due to the abnormal anatomy, the hemodynamic burden, or as a sequela of surgical treatment. Depending on the underlying mechanism, arrhythmias may arise in the early postoperative period (hours to days after surgery) or in the late postoperative period (usually years after surgery). A good understanding of the electrophysiological characteristics and pathophysiological mechanisms is therefore crucial to guide the therapeutic approach. Here, we synthesize the current state of knowledge on epidemiological features, risk factors, pathophysiological insights, electrophysiological features, and therapy regarding tachyarrhythmias in children and young adults undergoing reparative surgery for congenital heart disease. The evolution and latest data on treatment options, including pharmacological therapy, ablation procedures, device therapy decision, and thromboprophylaxis, are summarized. Finally, throughout this comprehensive review, knowledge gaps and areas for future research are also identified.

show abstract

Use of ivabradine in a critically ill pediatric patient with recalcitrant ectopic atrial tachycardia and complex congenital heart disease

Cited by 6 publications

References 15 publications

Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease

Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease

Antiarrhythmic Drug Dosing in Children—Review of the Literature

Early and Late Postoperative Tachyarrhythmias in Children and Young Adults Undergoing Congenital Heart Disease Surgery

Contact Info

Product

Resources

About